Beste Nabelschnurblutbehandlung Kinderärzte - TOP-20 Ärzte

Education:

1977 - 1984 - Medical Institute, specialty "Medical business"

Improving skills and acquiring new knowledge:

1990 - Clinical residency in the specialty "Cycle therapy with clinical cardiology", Kyiv

1992 - TU "Medical Radiology", Kharkiv

1995 - TU "Modern methods of diagnosis of internal diseases and rheumatology", Kyiv

1999 - TU "Organization of Medical Support of the Armed Forces", Kyiv

2004 - TU "Current issues of clinical arrhythmology in cardiology", Kyiv

2009 - TU "Current issues of therapy and rheumatology", Kyiv

2012 - TU "Fundamentals of geriatric knowledge", Kyiv

2013 – Institute for Advanced Training of Managerial Personnel of the National Academy of Sciences under the President of Ukraine, Kyiv

2014 - TU "Current issues of therapy and pulmonology", Kyiv

2016 - Specialization "organization and management of health care", Kyiv

2018 - TU "Current issues of internal diseases of the patient", Kyiv

2020 - TU "Current issues of therapy", Kyiv

2021 - TU "Current issues of internal diseases of the patient", Kyiv

2023 - TU "Current issues - clinical cardiology", Kyiv

The main areas of practical activity:

examination, anamnesis study and consultations on the treatment of diseases of a therapeutic profile

appointment of the necessary additional examination

interpretation of analysis results

appointment of an individual treatment plan and recommendations for disease prevention

control of therapy, recovery and rehabilitation measures

Participation in associations:

Association of therapists of Ukraine

Association of Cardiologists of Ukraine

Association of Gastroenterologists of Ukraine

Organization of medical care in EU countries

Association of Physiotherapists ("Karlovo Vary", Prague)

The therapist treats the following diseases:

SARS

acute bronchitis

pneumonia

State Public Enterprise

acute vasomotor rhinitis

chronic gastroduodenitis

ulcer disease

chronic cholecystitis

pancreatitis

NCD

hypertensive disease

CHD

gout

gouty polyarthritis

acute cystitis

metabolic disorders, obesity

Dr Supaporn Sompanwang, M.D.

General Pediatrician

Has Special training in preventing, diagnosing, and treating diseases and injuries in children. Pediatricians also help manage other problems that affect children, such as developmental disorders and behavioral, emotional, and social problems.

Graduated (M.D. From)

Doctor of Medicine, Faculty of Medicine, Naresuan University

Certificates

Certificate of Pediatrics, Buddhachinaraj Phitsanulok Hospital

Certificate of Family Medicine, Buddhachinaraj Phitsanulok Hospital

Current Positions

Pediatrician at Intrarat Hospital

Dr Panyapan Tiraprasidporn, M.D.

General Pediatrician

Special training in preventing, diagnosing, and treating diseases and injuries in children. Pediatricians also help manage other problems that affect children, such as developmental disorders and behavioral, emotional, and social problems.

Graduated (M.D. From)

Doctor of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University

Certificates

Certificate of Pediatrics, Faculty of Medicine, Siriraj Hospital, Mahidol University

Current Positions

General Pediatrician at Intrarat Hospital

Kanokkaew Viravan , M.D.

General Pediatrician, American Board of Pediatrics

Graduated (M.D. From)

Doctor of Medicine from Medical University of South Carolina, SC, USA

Certificates

Diplomate of the American Board of Pediatrics, Pennsylvania State University Children’s Hospital, PA, USA

Diplomate of National Board of Medical Examiners from USA

Certificate in Fundamentals of Occupational and Environmental Medicine, Burapha University

Certificate of Actively Attended and Participated as DELEGATE at the FUE Asia, Thailand ASEAN Regional Workshop
(LIVE HAIR TRANSPLANT WORKSHOP) : 23-24 August 2024

Current Positions

General Pediatrician at Intrarat Hospital

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

Education

• 2000, (Undergraduate / Graduate) Cerrahpaşa Faculty of Medicine, Istanbul University
• 2006, (PhD/ Specialty) Pediatrics, Istanbul Haydarpaşa Numune Training and Research Hospital

Experience

• 2001-2002, (Research Assistant) Istanbul Taksim First Aid Training and Research Hospital, Biochemistry Department
• 2002-2006, (Research Assistant) Istanbul Haydarpaşa Numune Training and Research Hospital
• 2006-2010, (Specialist) Bolu Izzet Baysal Women's Health and Pediatric Hospital
• 2010-2016, (Assistant Professor) Department of Pediatrics, Abant Izzet Baysal University Faculty of Medicine
• 2016, (Associate Professor) Department of Pediatrics, Abant Izzet Baysal University Faculty of Medicine
• 2018-2019, (Associate Professor) Istanbul Private Ersoy Hospital

2019-2024

, 

(Associate Professor)

 Istanbul Private Hisar Intercontinental Hospital

Education

GATA Haydarpaşa Training and Research Hospital Istanbul, Turkey

Residency program Sep 2011

Infectious Diseases and Clinical Microbiology Department fellowship program.

Gülhane Military Medical Academy Ankara, Turkey

Bachelor of Science: Medical School Aug 2003

Kuleli Military High School Istanbul, Turkey

High School Diploma Jul 1997

Experience

Health Sciences University Istanbul, Turkey

Associated Professor of Infectious Diseases Aug 2021 - Current

Associated Professor

Sisli Hamidiye Etfal Training and Research Hospital Istanbul, Turkey

Infectious Diseases Physician July 2020–August 2021

Infectious Diseases Physician

Yale School of Medicine Infectious Diseases Department New Haven, CT, USA

Associate Research Scientist June 2019- June2020

Research to improve vaccine against Tick Borne Diseases (Lyme Diseases, Babesiosis etc.)

Yale School of Medicine Infectious Diseases Department New Haven, CT, USA

Visiting Research Scientist Jul 2018 - June2019

Research to improve vaccine against Tick Borne Diseases (Lyme Diseases, Babesiosis etc.)

Turkish Ministry of Health Ankara, Turkey

Head of Health Tourism unit Feb 2017 - June 2018

Improving the health tourism policy of Turkey.

Sisli Hamidiye Etfal Training and Research Hospital Istanbul, Turkey

Infectious Diseases Physician Aug 2016 - June 2018

Infectious Diseases Physician

Tatvan Military Hospital Bitlis , Turkey

Infectious Diseases Physician Jul 2013 - Aug 2016

Infectious Diseases physician

Girne Military Hospital Turkish Republic of Northern Cyprus

Infectious Diseases Physician Oct 2011 - Jun 2013

Infectious diseases physician

GATA Training and Research Hospital Istanbul, Turkey

Residency period Jul 2006 - Sep 2011

4 th. Mechanized Infantry Brigade Command Edirne, Kesan, Turkey

Medical Doctor, May 2004 - Jun 2006

Maintaining the basic health services of the military unit.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA

ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.

TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.

TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA

ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.

TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.

TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA

ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.

TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.

TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA

ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.

TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.

TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA

ESPECIALISTA EN MEDICINA REGENERATIVA Y ANTIENVEJECIMIENTO.

TRATAMIENTO DE ENFERMEDADES DEGENERATIVAS.

TERAPIAS ANTIENVEJECIMIENTO MEDIANTE USO DE CELULAS MADRE, DERIVADOS, TERAPIA DE REEMPLAZO HORMONAL Y SUEROTERAPIA.

MIEMBRO ACTIVO DEL CONSEJO DE MEDICOS CIRUJANOS CON FINES DE INVESTIGACION.

MIEMBRO DEL CONSEJO MEXICANO DE CELULAS TRONCALES  CON FINES TERAPEUTICOS Y DE INVESTIGACION.

MIEMBRO DEL COLEGIO MEXICANO DE CELULAS MADRE Y MEDICINA REGENERATIVA.

Dr. Lara ist eine leidenschaftliche Ärztin aus Honduras mit mexikanischem Herzen. Sie erwarb ihren Doktortitel an der Katholischen Universität von Honduras und hat einen Postgraduiertenabschluss in Adipositasmedizin von der Universidad Iberoamericana in Mexiko-Stadt. Anschließend absolvierte sie einen Master in angewandter Ernährung mit Schwerpunkt Forschung an der Universidad Iberoamericana in Mexiko-Stadt, wo ihr Engagement, auf dem neuesten Stand zu bleiben, und ihre Leidenschaft für evidenzbasierte Medizin immer stärker wurden.

Sie ist Mitglied der International Society for Stem Cell Application, SCOPE-zertifiziert von der World Obesity Federation und zertifiziert für Sport- und Trainingsernährung.

Neben ihrer klinischen Erfahrung in mehreren Krankenhaus-Notaufnahmen und in ihrer Privatpraxis verfügt Dr. Lara über umfangreiche Erfahrung im Bereich der regenerativen Medizin, wo ihr größtes Ziel darin besteht, das Leben ihrer Patienten positiv zu beeinflussen. Sie hat auch Erfahrung in Verwaltungsbereichen in Mexiko, wo sie neben der Überwachung von Behandlungen auch über die neuesten mexikanischen Regulierungsgesetze (COFEPRIS) informiert ist. Ihre Leidenschaften sind Medizin und Sport, und sie hat es geschafft, beides zu verbinden, sowohl in ihrer Berufswelt als auch in ihrem Privatleben.

Leiter der Lehre am Puerto Vallarta Regional Hospital

2020-2023

Klinischer Aktenmanager am Puerto Vallarta Regional Hospital 2 Monate 2020

Allgemeinmediziner in privater Arztpraxis

2015-2022

Verantwortlicher Arzt der Klinik für Gewichtskontrolle

2013-2014

Medizinischer Assistent in der Hautklinik

2008-2013

Medizinischer Assistent bei dermatologischen Eingriffen.

 Medizinischer Assistent bei minimalinvasiven chirurgischen Eingriffen

 Betrieb der fraktionierten Lasermaschine - IPIXEL-ER und

Gesichtsverjüngung mit IPL.

 Erfahrung in der Laser-Haarentfernung mit Intense Pulsed Light und

Radiofrequenz

 Erfahrung mit Ultraschallkavitation

 Erfahrung mit UV-Licht-Phototherapiegeräten für

Behandlung von Psoriasis und Vitiligo.

 Erfahrung in der Unterstützung bei Botox- und Filler-Eingriffen.

 Biomagnet zertifiziert vom Higher Institute of Biomagnetism

Arzt ISAAC GOIZ DURAN

 Erfahrung mit klinischen Aufzeichnungen

 Ausbildung in Weiterbildung und Lehrerfortbildung

Ausbildung:

2010 - 2016 - Nationale Medizinische Universität benannt nach OO Bogomolets, Fachrichtung "Medizingeschäft"

2017 - Abschluss eines Praktikums im Bereich „Labordiagnostik“

2018 – Ukrainische Militärmedizinische Akademie, Fachrichtung „Dermatovenerologie“

2021 - Dozent der Abteilung VZPSM im Studiengang „Dermatovenerologie“, Ukrainische Militärmedizinische Akademie

2021 - zertifizierter Trainer für Injektionstechniken

Seit 2017 - Dermatologin, Kosmetikerin bei Mediland MC

Fähigkeiten verbessern und neues Wissen erwerben:

2017 - Kurse im Rahmen des Programms "Kosmetikerin, Körperkosmetikerin" an der Schule für Kosmetologie und ästhetische Medizin "Partner +"

2017 - Kurse im Rahmen des Programms „Spezialist für Injektionstechniken: Mesotherapie, Biorevitalisierung, Botulinumtherapie, Konturplastische Chirurgie“

2017 - Teilnehmer des III. Allukrainischen Symposiums der Firma für Kosmetologie

2018 - Kurs im Programm "Trichologie"

2018 - Kurs im Rahmen des Programms "Plasmotherapie"

2018 - Kurs im Rahmen des Programms „Konturplastik in der ästhetischen Medizin“

2018 - Kurs im Rahmen des Programms „PRX-T33 – Injektionsfreies Dermal Remodeling“

2018 - Schulung in Lasertechniken „Laserschulung zu: Motus, MINISILK_FT, YNCHRO_FT“

2018 - Teilnehmer des 4. Allukrainischen Symposiums „Unternehmen für Kosmetologie“

2020 - „MEDfocus: Dialog der Fachleute“ Moderne Ansätze in Dermatologie und ästhetischer Medizin

2020 - „DERM SUMMIT“ Internationaler wissenschaftlicher und praktischer virtueller Gipfel für Ärzte aller Fachrichtungen und Patienten zu dermatologischen Themen

2021 - „Melanom-Tage 2021“

2021 – „Akne, Rosazea und chronische Dermatosen des Gesichts“ im Rahmen des Frühjahrssymposiums 2021.

2021 - "Akademie für Trichologie"

2021 – „S-Kongress 3.0“

2021 – „Fortschrittliche Dermatologie: vielfältige Möglichkeiten und Lösungen“

2022 - Akademische Lesungen benannt nach Volodymyr Pask im Rahmen der 31. Internationalen Medizinausstellung „PUBLIC HEALTH 2022“

2022 - „MELANOMTAG 2022“

Ist ein gültiges Mitglied:

Ukrainischer Verband der Dermatologen und Kosmetiker UADVC

Internationale Vereinigung für ästhetische Kosmetologie und Mesotherapie MAEKM

Der Arzt ist Experte im TV-Projekt „Ich schäme mich für meinen Körper“ (Kanal STB) – er führt Beratungen durch, diagnostiziert und behandelt Patienten, die Helden des Projekts.

Zertifizierter Trainer für Injektionstechniken der Firma MedHome für die Medikamente Twac und Phillex. Dozent der Abteilung der Ukrainischen Akademie der Medizinischen Wissenschaften für den Kurs „Dermatovenerologie“, Ukrainische Militärmedizinische Akademie

Ein Trichologe bzw. Dermatologe diagnostiziert und behandelt Erkrankungen der Gesichts- und Körperhaut, der Nägel und Haare wie:

Akne, Hautreizungen, Akne, Postakne

Rosacea

Demodikose

seborrhoische Dermatitis

Hautneoplasien - Warzen, Papillome usw.

Alopezie oder Haarausfall verschiedener Art (Untersuchung mit Trichoskop und Laboruntersuchungen, Verschreibung einer konservativen Behandlung, Behandlung mit Injektionsbehandlungsmethoden)

Onychomykose oder Nagelpilz

andere Erkrankungen der Haut des Gesichts, des Körpers, der Haare

Durchgeführte Verfahren zur Diagnose und Behandlung dermatologischer Erkrankungen:

Dermatoskopie

Radiowellenentfernung von Hautneoplasmen mit dem Surgitron-Gerät

Kryodestruktion von Hautneoplasmen - Warzen, Papillome

Kryomassage der Haut von Gesicht, Körper und Kopfhaut

Trichoskopie der Kopfhaut und der Haarfollikel

Der Arzt erstellt je nach Hauttyp und Zustand ein individuelles umfassendes Hautpflegeprogramm

Die Kosmetikerin führt folgende Eingriffe durch:

Laserkosmetik:

Laserepilation

Laserschleifen

Fotoverjüngung

Kohlenstoffpeeling

Klassische Kosmetik:

mechanische Reinigung des Gesichts

Ultraschall-Gesichtsreinigung

chemische Peelings

Gesichtsmassage

Carboxytherapie

Hautpflegeverfahren

umfassende Hautpflegeprogramme

Hardware-Kosmetik:

Vorgehensweise bei „Futura PRO“

Ultraschall-Gesichtsmassage

Mikrostrom

Myostimulation von Gesicht und Körper

Biostimulation von Gesicht und Körper

Darsonval des Gesichts und der Kopfhaut

Injektionskosmetik:

Mesotherapie von Gesicht, Körper und Kopfhaut/Haar

Biorevitalisierung

Revitalisierung "Aquashine"

Botulinumtherapie

Kontur Kunststoff

Plasma-Lifting oder PRP-Therapie

Kryotherapie:

Kryomassage der Gesichtshaut, des Dekolletés, des Rückens

Kryomassage der Kopfhaut